Education
About Us
Working with TipRanks
Follow Us
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
KPRX Stock Chart & Stats
$1.80
-$0.13(-3.22%)
At close: 4:00 PM EST
$1.80
-$0.13(-3.22%)
Day’s Range― - ―
52-Week Range$1.91 - $4.18
Previous CloseN/A
Volume13.46K
Average Volume (3M)36.18K
Market Cap
$8.14M
Enterprise Value-$8.53M
Total Cash (Recent Filing)$19.38M
Total Debt (Recent Filing)$404.17K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 31, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding3,433,491
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.50
Price to Sales (P/S)0.80
P/FCF Ratio1.49
Enterprise Value/Market Cap-1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit223.03
Enterprise Value/Ebitda1.17
Forecast
1Y Price Target
$11.00Price Target Upside511.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsKiora is now advancing both Phase 2 studies for its flagship programs, KIO-301 and KIO-104.
Financial StabilityThe company ended the period with $19.4M in cash, providing funding into late 2027, with potential to be extended further via potential agreements.
Strategic PartnershipsKiora has secured multiple commercial agreements for KIO-301, including a partnership with Laboratories Théa for global rights ex-Asia and a partnership agreement with Senju Pharmaceutical Co. for commercialization in Asia.
Bears Say
Clinical Trial RisksRisks include failure of KIO-301 in clinical trials, failure to secure regulatory approval, and potential commercial challenges related to reimbursement and competition.
Kiora Pharmaceuticals News
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $1.91 and its highest was $4.18 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $8.14M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 129 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Nov 07, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.745.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.67.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 3,433,491 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went up 0.431%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
KPRX Stock 12 Month Forecast
Average Price Target
$11.00
▲(511.11% Upside)
Technical Analysis
Genprex
―
Dogwood Therapeutics
―
Sensei Biotherapeutics
―
TransCode Therapeutics
―
AEON Biopharma
―
Ownership Overview
2.98% Insiders
0.62% Mutual Funds
13.64% Other Institutional Investors
82.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---